Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Demant rises sharply after double upgrade by BofA
The Demant share climbed about 3.5% today after BofA Securities raised its rating from "Underperform" to "Buy" and increased the price target from DKK 170 to DKK 280. BofA justified the upgrade with stronger market growth in the first quarter, improved demand for the Oticon Zeal product, raised EPS forecasts for 2026 and 2027, and lower capital costs. The revaluation pushed the stock toward the new price target and supports a recovery thesis for Demant. » Plus sur de.investing.com
Demant exceeds Q1 revenue forecast thanks to Oticon Zeal and acquisitions
Demant reports Q1 2026 revenue of USD 6.25 billion, 2.46% above the USD 6.1 billion forecast. Total growth was 16%, driven by 6% organic growth and 10% acquisition-driven growth (mainly from the acquisition of KIND); EPS met expectations. Strong sales in North America and Europe and the launch of Oticon Zeal lifted the gross margin, and the stock rose 0.97% after hours to USD 209.2. Management confirms the 2026 outlook and remains confident about further product launches in the second half of the year. » Plus sur de.investing.com
Demant beats Q1 revenue forecast thanks to hearing-aid growth, stock jumps sharply
Demant reported Q1 2026 revenue of USD 6.25 billion, exceeding the USD 6.1 billion forecast. Drivers were 6% organic growth and roughly 10% acquisition-driven growth following the integration of KIND, as well as the product launch of Oticon Seal, which led to an expansion of gross margin. The stock rose 10.9% to USD 232 after the announcement. Management confirmed the full-year guidance for organic growth of 3–6% and an EBIT range of DKK 4.1–4.5 billion, but cited currency risks and potential market saturation as challenges. » Plus sur de.investing.com
William Demant falls 13% after quarterly results
William Demant reported acquisition-driven revenue growth in Q4 2025, while EBIT before special items fell 10% and free cash flow declined 11%. The takeover of the KIND group increased net debt and pushed the leverage ratio to 3.4, prompting management to suspend share buybacks and prioritize debt reduction. Newly introduced premium hearing aid Oticon Seal is expected to drive growth but failed to reassure investors. For 2026 the company expects organic growth of 3–6% and an EBIT of DKK 4.1–4.5 billion; a return to the leverage target is planned within 18–24 months. » Plus sur de.investing.com
Demant acquires Kind and becomes Germany's largest hearing-aid chain
The Federal Cartel Office has approved the takeover of around 600 Kind branches by the Danish group Demant. Demant is also buying Audifon, the manufacturer owned by Kind, combining about 350 of its own branches in Germany with the acquired locations. The authority considers there to be sufficient competition from other chains, opticians and regional providers despite the merger. The Kind brand name is to be retained, and the previous owning family will withdraw after the transaction is completed. » Plus sur spiegel.de
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2000, Demant a déjà versé 0,0802 € de dividendes. Le dernier versement a eu lieu en mai 2000.
Données financières
Au dernier trimestre, Demant a réalisé un chiffre d'affaires de 1,73 Md € et un bénéfice net de 158,11 M €
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 1,73 Md | - |
| Bénéfice brut | 1,34 Md | - |
| Bénéfice net | 158,11 M | - |
| EBITDA | 413,66 M | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 10,25 Md € |
Nombre d'actions | 210,9 M |
Plus haut/bas sur 52 semaines | 49,02 € - 25,57 € |
| Dividendes | Non |
Bêta | 0,76 |
Ratio P/E | 44,72 |
Ratio PEG | -1,54 |
Ratio P/B | 6,41 |
Ratio P/S | 2,93 |
Profil de l'entreprise
Demant A/S, entreprise spécialisée dans la santé auditive et la technologie audio, conçoit, fabrique et commercialise des produits et équipements destinés à améliorer l'audition des personnes en Europe, en Amérique du Nord, dans le Pacifique, en Asie et à l'international. Elle exerce son activité dans deux segments, Hearing Healthcare et Communications. Le segment Hearing Healthcare propose des implants et appareils auditifs, des services de soins auditifs et des produits de diagnostic. Le segment Communications fournit des casques pour le travail collaboratif et le marché du jeu vidéo, sous la marque EPOS. La société était auparavant connue sous le nom de William Demant Holding A/S et a changé de nom pour devenir Demant A/S en mars 2019. Demant A/S a été fondée en 1904 et son siège social se trouve à Smørum, au Danemark.
| Nom | Demant |
| PDG | Søren Nielsen |
| Siège social | Smørum,
ze Danemark |
| Site web | |
| Secteur | Santé |
| Industrie | Équipements et fournitures médicaux |
| Introduction en bourse | 08/05/2000 |
| Employés | 26 704 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
Pnk | WILLF |
Nasdaq Copenhagen | DEMANT.CO |
Copenhagen | DEMANT.CO |
Frankfurt | WDH1.F |
Düsseldorf | WDH1.DU |
London | 0RGT.L |
SIX | WDH.SW |
München | WDH1.MU |
Wien | DEMA.VI |